Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O'Grady as its Chief Executive Officer. Mr. O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O'Grady succeeds Dan Teleman, with the leadership transition effective July 27, 2026.
Covered in this story
What has happened since
- TE Connectivity is up 2.2% since this was published, 69 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $TEL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TE Connectivity →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.